A collision on a ski slope led to Liz Healy being diagnosed with two rare cancers. Two months later, she underwent a 10-hour ...

Cold endoscopic mucosal resection (EMR) demonstrates lower rates of delayed bleeding and perforation but a higher risk for recurrent or residual neoplasia than hot EMR in colorectal polyp treatment.

Emily King of Mobile, Alabama, was diagnosed with colon cancer five years ago at the age of 27. She had experienced some diarrhea, abdominal pain and anemia, but having cancer had never entered ...

CARDIFF, UK / ACCESS Newswire / February 12, 2025 /Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage ...

Ms Lauren V O’Connell was recently announced by the Royal College of Surgeons in Ireland (RCSI) as the recipient of the 2025 ...

A phase Ib study of immunotherapy with ex-vivo pre-activated and expanded CBNK cells in combination with cetuximab, in patients with colorectal cancer (CRC) with minimal residual disease (MRD): Final ...

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a ...

The modified intention-to-treat analysis included 1,550 colorectal cancer patients who had undergone resection and had completed standard adjuvant therapy (at least 3 months of chemotherapy).

Investigators included adults with Dukes' C or high-risk Dukes' B colon cancer or Dukes' B or C rectal cancer who completed resection and at least three months of chemotherapy. Patients were ...

The U.K. biopharmaceutical company said data from a Phase 2 study of eRapa, a treatment for familial adenomatous polyposis, showed the drug to be safe and well-tolerated among users. The treatment ...

In a recent study published in the Journal of Crohn’s and Colitis, researchers showed that oral vancomycin (OV) induces ...

CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatmen ...